-
Clinical Briefs: Coffee Might be One Less Thing We Have to Worry About; ED, Lower Urinary Tract Symptoms, and Ejaculatory Dysfunction; The Allure of Shared Medical Appointments in Diabetes Care
-
A BETA-3 ADRENERGIC AGONIST HAS BEEN APPROVED FOR the treatment of overactive bladder in adults. Mirabegron differs from other agents approved for this same indication, such as oxybutynin, tolterodine, solifenacin, darifenacin, etc., which are anticholinergic/antimuscarinic agents. Mirabegron is marketed by Astellas Pharma as Myrbetriq.
-
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
-
While Prevnar 13 has received FDA approval for use in adults aged 50 years and older, the CDC recommends continued use of the 23-valent polysaccharide pneumococcal vaccine until further information becomes available.
-
In a meta-analysis of current observational (both case-control and prospective cohort) studies evaluating the potential association between type 2 diabetes mellitus and the incidence of hematological malignancy, an increased risk for non-Hodgkin lymphoma and leukemia was demonstrated as well as a trend toward an increased risk for myeloma.
-
The benefits of regular physical activity are well known. Encouraging individuals to be active through recreational and competitive athletics while preventing and treating injuries is the role of the sports medicine physician.
-
The authors conclude that after weight loss, a low glycemic index and, to a lesser extent, low-protein diet may reduce inflammation associated with cardiovascular disease in overweight adults.
-
There is perhaps no greater public health passion than that for fighting cancer. There is also perhaps no greater confusion than that surrounding nutrition and cancer. Public "cancer scares" regarding environmental exposures and alternative treatments often capture the public's attention.
-
A new angiotensin ii receptor blocker (ARB) and the thiazide diuretic, chlorthalidone, has been approved as a fixed combination for the treatment of hypertension.
